Cargando…

Treatment of systemic-onset juvenile arthritis with canakinumab

Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peitz, Joachim, Horneff, Gerd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045123/ https://www.ncbi.nlm.nih.gov/pubmed/27790042 http://dx.doi.org/10.2147/OARRR.S54215

Ejemplares similares

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
por: Quartier, Pierre, et al.
Publicado: (2020)

Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
por: Bakry, Reima, et al.
Publicado: (2022)

Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease in the U.S. Real-World Settings
por: Hur, Peter, et al.
Publicado: (2021)

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
por: Ruperto, Nicolino, et al.
Publicado: (2018)

Predictors of response to methotrexate in juvenile idiopathic arthritis
por: Albarouni, Mohamed, et al.
Publicado: (2014)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
por: Brachat, Arndt H., et al.
Publicado: (2017)

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis
por: Kostik, Mikhail M., et al.
Publicado: (2022)

Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses
por: Dunger-Baldauf, Cornelia, et al.
Publicado: (2022)

Juvenile idiopathic arthritis with systemic onset with inflammatory bone lesions: two case reports of patients successfully treated with canakinumab and experience gained from literature
por: Alexeeva, Ekaterina I., et al.
Publicado: (2023)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017)

PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis
por: Xiong, Y, et al.
Publicado: (2013)

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

Prevalence and risk factors of depressive symptoms in children and adolescents with juvenile idiopathic arthritis
por: Roemer, Johanna, et al.
Publicado: (2023)

PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2013)

Early Treatment of Systemic Juvenile Idiopathic Arthritis with Canakinumab and Complete Remission After 2 Years of Treatment Suspension: Case Report of an Adolescent Girl
por: Maggio, Maria Cristina, et al.
Publicado: (2019)

Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity
por: Kudela, Holger, et al.
Publicado: (2019)

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
por: Nirmala, N, et al.
Publicado: (2013)

Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease
por: Shaul, Eliana, et al.
Publicado: (2022)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2017)

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study
por: Ruperto, N, et al.
Publicado: (2011)

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review
por: Horneff, Gerd, et al.
Publicado: (2023)

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
por: Klotsche, Jens, et al.
Publicado: (2021)

Treatment of patients with systemic-onset juvenile idiopathic arthritis with tacrolimus
por: Wang, Dongdong, et al.
Publicado: (2019)

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Thiele, Franz, et al.
Publicado: (2021)

Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
por: Galozzi, Paola, et al.
Publicado: (2018)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Canakinumab treat-to target strategies increase complete response rate in CAPS
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Cervical spine involvement in patients with juvenile idiopathic arthritis - MRI follow-up study
por: Hospach, Toni, et al.
Publicado: (2014)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami, Miho, et al.
Publicado: (2012)

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab
por: Ghannam, Khetam, et al.
Publicado: (2021)

German evidence- and consensus-based guidelines 2011 for the treatment of juvenile idiopathic arthritis (JIA)
por: Dueckers, Gregor, et al.
Publicado: (2012)

Anakinra treatment in patients with systemic-onset juvenil idiopathic arthritis: “The Valencia Experience”
por: Marvillet, I, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_mimebkg4u89kr0mg9s9cikjfrn